---
title: "Scilex Holding Company (SCLX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/SCLX.US.md"
symbol: "SCLX.US"
name: "Scilex Holding Company"
industry: "制药"
---

# Scilex Holding Company (SCLX.US)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 美股市场 |
| Website | [www.scilexholding.com](https://www.scilexholding.com) |

## Company Profile

Scilex Holding Company 专注于收购、开发和商业化非阿片类疼痛管理产品，以治疗急性和慢性疼痛。其商业产品包括 ZTlido（利多卡因外用系统）1.8%（ZTlido），这是一种处方利多卡因外用产品，用于缓解与带状疱疹后神经痛（PHN）相关的神经性疼痛；ELXYB，一种即用型口服溶液，用于成人急性偏头痛的治疗，无论是否伴有先兆；以及 GLOPERBA，一种液体口服版本的抗痛风药物秋水仙碱，适用于成人痛风发作的预防。该公司还开发了三种产品候选药物，包括 SP-102（10 毫克，磷酸氟氯噻吨粘稠凝胶 - SEMDEXA），这是一种用于硬膜外注射的已使用的皮质类固醇的新型粘稠凝胶...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-19T04:30:16.000Z

**Overall: D (0.69)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 147 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -26.82% |  |
| Net Profit YoY | -328.32% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -0.39 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 69.80M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 40.36M |  |


**Multi Score**: D

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 193.60% | A |
| Profit Margin | -822.80% | E |
| Gross Margin | 68.48% | A |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -26.82% | E |
| Net Profit YoY | -328.32% | E |
| Total Assets YoY | 174.70% | A |
| Net Assets YoY | 14.95% | A |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -10.74% | D |
| OCF YoY | -26.82% | E |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.21 | D |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 165.14% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Scilex Holding Company",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "193.60%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-822.80%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "68.48%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-26.82%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-328.32%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "174.70%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "14.95%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-10.74%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-26.82%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.21",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "165.14%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 礼来 (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | 罗氏(ADR) (US.RHHBY) | A | B | B | D | C | B |
| 04 | 阿斯利康 (US.AZN) | A | B | C | D | C | B |
| 05 | 诺华制药 (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.19 | 70/257 | - | - | - |
| PB | -0.39 | 199/257 | - | - | - |
| PS (TTM) | 1.73 | 44/257 | 2.52 | 1.75 | 0.65 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-24T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 1 | 100% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 8.29 |

## References

- [Company Overview](https://longbridge.com/en/quote/SCLX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/SCLX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/SCLX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.